neonati

Impatto preliminare della profilassi universale con nirsevimab in ambito neonatale: esperienza monocentrica di Bergamo

Colombo M, Ferrari S, Mangili G

2025/6 — pag. 131-137 — DOI

Respiratory Syncytial Virus (RSV) is the main cause of hospitalisation in infants. The present single-centre observational study aimed to analyse the adherence to universal prophylaxis with Nirsevimab and to evaluate its preliminary effectiveness in ...

Nirsevimab come immunoprofilassi universale dell’infezione da virus respiratorio sinciziale?

Marchetti F, Addis A.

2023/3 — pag. 155-158 — DOI

The important therapeutic news regarding the availability of the monoclonal antibody nirsevimab for the prophylaxis of the respiratory syncytial virus infection with a single dose has opened up a significant debate on the opportunity of its use for u...

Lo stroke ischemico nel bambino

A. Iacono, C. Guiducci, G. Turlà, C. Renzelli, P. Ricciardelli, F. Marchetti

2018/7 — pag. 425-431

Ischemic stroke is a clinical syndrome characterised by the sudden onset of a neurological deficit that can refer to the perfusion area of a cerebral artery and by the neuroradiologic evidence of an ischemic lesion. The incidence of ischemic stroke...

Neonati e Streptococco di gruppo B: come semplificarsi la vita

S. Demarini

2013/8 — pag. 483-485